ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF study

Daniele Pastori, Alessio Farcomeni, Pasquale Pignatelli, Francesco Violi, Gregory Yh Lip

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

5 Citationer (Scopus)

Resumé

BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway for the integrated approach to the management of patients with atrial fibrillation has been proposed to streamline patient management in an integrated, holistic manner, as follows: 'A' Avoid stroke with Anticoagulation; 'B' Better symptom management, with rate or rhythm control; 'C' Cardiovascular risk and comorbidity management, including lifestyle factors. ABC pathway compliance has been associated with a reduced rate of cardiovascular events compared to non-ABC compliant patients. However, the impact of the ABC pathway on health-related costs has not been evaluated.

METHODS: We performed an exploratory analysis of costs related to cardiovascular events in the ATHERO-AF study, which is a prospective single-center cohort study including atrial fibrillation patients treated with vitamin K antagonists. A Diagnosis-Related Group code provided by the Italian Ministry of Health was assigned to each cardiovascular event by event typology to estimate the relative cost. The analysis was performed by dividing patients according to ABC pathway components.

RESULTS: Overall, the 118 cardiovascular events in the cohort incurred a cost of 1,017,354 euros (1,149,610 USD). The mean total costs were 13,050 (14,747 USD) and 11,218 euros (12,676 USD) for a non-fatal cardiac event or ischaemic stroke, respectively. The highest costs were related to cardiac complications, followed by non-fatal ischaemic stroke and cardiovascular death. Based on the ABC pathway components, the cost-saving was 719 euros (813 USD) per patient-year for patients in group A vs non-A, 703 euros (794 USD) for B vs non-B, 480 euros (542 USD) for C vs non-C and 2776 euros (3,137 USD) for ABC vs non-ABC. The cost per cardiovascular event increased with the number of uncontrolled ABC components: 0-1: 507 euros (573 USD), raising to 965 euros (1,091 USD) for 2 components and to 3,431 euros (3,877 USD) for patients not having any of the three components of the ABC.

CONCLUSIONS: Management of atrial fibrillation patients according to the ABC pathway was associated with significantly lower health-related costs. Application of the ABC pathway as a management strategy may help reduce healthcare costs related to cardiovascular events in this high-risk patient population.

OriginalsprogEngelsk
TidsskriftThe American Journal of Medicine
Vol/bind132
Udgave nummer7
Sider (fra-til)856-861
Antal sider6
ISSN0002-9343
DOI
StatusUdgivet - jul. 2019

Fingerprint

Health Care Costs
Atrial Fibrillation
Costs and Cost Analysis
Stroke
Vitamin K
Diagnosis-Related Groups
Risk Management
Compliance
Life Style
Comorbidity
Patient Care
Cohort Studies
Myocardial Infarction

Bibliografisk note

Copyright © 2019. Published by Elsevier Inc.

Citer dette

Pastori, Daniele ; Farcomeni, Alessio ; Pignatelli, Pasquale ; Violi, Francesco ; Lip, Gregory Yh. / ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation : The ATHERO-AF study. I: The American Journal of Medicine. 2019 ; Bind 132, Nr. 7. s. 856-861.
@article{7980458956294a8eb6cff2ff33dfcc3b,
title = "ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF study",
abstract = "BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway for the integrated approach to the management of patients with atrial fibrillation has been proposed to streamline patient management in an integrated, holistic manner, as follows: 'A' Avoid stroke with Anticoagulation; 'B' Better symptom management, with rate or rhythm control; 'C' Cardiovascular risk and comorbidity management, including lifestyle factors. ABC pathway compliance has been associated with a reduced rate of cardiovascular events compared to non-ABC compliant patients. However, the impact of the ABC pathway on health-related costs has not been evaluated.METHODS: We performed an exploratory analysis of costs related to cardiovascular events in the ATHERO-AF study, which is a prospective single-center cohort study including atrial fibrillation patients treated with vitamin K antagonists. A Diagnosis-Related Group code provided by the Italian Ministry of Health was assigned to each cardiovascular event by event typology to estimate the relative cost. The analysis was performed by dividing patients according to ABC pathway components.RESULTS: Overall, the 118 cardiovascular events in the cohort incurred a cost of 1,017,354 euros (1,149,610 USD). The mean total costs were 13,050 (14,747 USD) and 11,218 euros (12,676 USD) for a non-fatal cardiac event or ischaemic stroke, respectively. The highest costs were related to cardiac complications, followed by non-fatal ischaemic stroke and cardiovascular death. Based on the ABC pathway components, the cost-saving was 719 euros (813 USD) per patient-year for patients in group A vs non-A, 703 euros (794 USD) for B vs non-B, 480 euros (542 USD) for C vs non-C and 2776 euros (3,137 USD) for ABC vs non-ABC. The cost per cardiovascular event increased with the number of uncontrolled ABC components: 0-1: 507 euros (573 USD), raising to 965 euros (1,091 USD) for 2 components and to 3,431 euros (3,877 USD) for patients not having any of the three components of the ABC.CONCLUSIONS: Management of atrial fibrillation patients according to the ABC pathway was associated with significantly lower health-related costs. Application of the ABC pathway as a management strategy may help reduce healthcare costs related to cardiovascular events in this high-risk patient population.",
author = "Daniele Pastori and Alessio Farcomeni and Pasquale Pignatelli and Francesco Violi and Lip, {Gregory Yh}",
note = "Copyright {\circledC} 2019. Published by Elsevier Inc.",
year = "2019",
month = "7",
doi = "10.1016/j.amjmed.2019.01.003",
language = "English",
volume = "132",
pages = "856--861",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier",
number = "7",

}

ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation : The ATHERO-AF study. / Pastori, Daniele; Farcomeni, Alessio; Pignatelli, Pasquale; Violi, Francesco; Lip, Gregory Yh.

I: The American Journal of Medicine, Bind 132, Nr. 7, 07.2019, s. 856-861.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation

T2 - The ATHERO-AF study

AU - Pastori, Daniele

AU - Farcomeni, Alessio

AU - Pignatelli, Pasquale

AU - Violi, Francesco

AU - Lip, Gregory Yh

N1 - Copyright © 2019. Published by Elsevier Inc.

PY - 2019/7

Y1 - 2019/7

N2 - BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway for the integrated approach to the management of patients with atrial fibrillation has been proposed to streamline patient management in an integrated, holistic manner, as follows: 'A' Avoid stroke with Anticoagulation; 'B' Better symptom management, with rate or rhythm control; 'C' Cardiovascular risk and comorbidity management, including lifestyle factors. ABC pathway compliance has been associated with a reduced rate of cardiovascular events compared to non-ABC compliant patients. However, the impact of the ABC pathway on health-related costs has not been evaluated.METHODS: We performed an exploratory analysis of costs related to cardiovascular events in the ATHERO-AF study, which is a prospective single-center cohort study including atrial fibrillation patients treated with vitamin K antagonists. A Diagnosis-Related Group code provided by the Italian Ministry of Health was assigned to each cardiovascular event by event typology to estimate the relative cost. The analysis was performed by dividing patients according to ABC pathway components.RESULTS: Overall, the 118 cardiovascular events in the cohort incurred a cost of 1,017,354 euros (1,149,610 USD). The mean total costs were 13,050 (14,747 USD) and 11,218 euros (12,676 USD) for a non-fatal cardiac event or ischaemic stroke, respectively. The highest costs were related to cardiac complications, followed by non-fatal ischaemic stroke and cardiovascular death. Based on the ABC pathway components, the cost-saving was 719 euros (813 USD) per patient-year for patients in group A vs non-A, 703 euros (794 USD) for B vs non-B, 480 euros (542 USD) for C vs non-C and 2776 euros (3,137 USD) for ABC vs non-ABC. The cost per cardiovascular event increased with the number of uncontrolled ABC components: 0-1: 507 euros (573 USD), raising to 965 euros (1,091 USD) for 2 components and to 3,431 euros (3,877 USD) for patients not having any of the three components of the ABC.CONCLUSIONS: Management of atrial fibrillation patients according to the ABC pathway was associated with significantly lower health-related costs. Application of the ABC pathway as a management strategy may help reduce healthcare costs related to cardiovascular events in this high-risk patient population.

AB - BACKGROUND: The Atrial fibrillation Better Care (ABC) pathway for the integrated approach to the management of patients with atrial fibrillation has been proposed to streamline patient management in an integrated, holistic manner, as follows: 'A' Avoid stroke with Anticoagulation; 'B' Better symptom management, with rate or rhythm control; 'C' Cardiovascular risk and comorbidity management, including lifestyle factors. ABC pathway compliance has been associated with a reduced rate of cardiovascular events compared to non-ABC compliant patients. However, the impact of the ABC pathway on health-related costs has not been evaluated.METHODS: We performed an exploratory analysis of costs related to cardiovascular events in the ATHERO-AF study, which is a prospective single-center cohort study including atrial fibrillation patients treated with vitamin K antagonists. A Diagnosis-Related Group code provided by the Italian Ministry of Health was assigned to each cardiovascular event by event typology to estimate the relative cost. The analysis was performed by dividing patients according to ABC pathway components.RESULTS: Overall, the 118 cardiovascular events in the cohort incurred a cost of 1,017,354 euros (1,149,610 USD). The mean total costs were 13,050 (14,747 USD) and 11,218 euros (12,676 USD) for a non-fatal cardiac event or ischaemic stroke, respectively. The highest costs were related to cardiac complications, followed by non-fatal ischaemic stroke and cardiovascular death. Based on the ABC pathway components, the cost-saving was 719 euros (813 USD) per patient-year for patients in group A vs non-A, 703 euros (794 USD) for B vs non-B, 480 euros (542 USD) for C vs non-C and 2776 euros (3,137 USD) for ABC vs non-ABC. The cost per cardiovascular event increased with the number of uncontrolled ABC components: 0-1: 507 euros (573 USD), raising to 965 euros (1,091 USD) for 2 components and to 3,431 euros (3,877 USD) for patients not having any of the three components of the ABC.CONCLUSIONS: Management of atrial fibrillation patients according to the ABC pathway was associated with significantly lower health-related costs. Application of the ABC pathway as a management strategy may help reduce healthcare costs related to cardiovascular events in this high-risk patient population.

U2 - 10.1016/j.amjmed.2019.01.003

DO - 10.1016/j.amjmed.2019.01.003

M3 - Journal article

VL - 132

SP - 856

EP - 861

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 7

ER -